A view on EGFR-targeted therapies from the oncogene-addiction perspective

A view on EGFR-targeted therapies from the oncogene-addiction perspective

Tumor cell growth and survival can often be impaired by inactivating a single oncogen – a phenomenon that has been called as 'oncogene addiction'. It is in such scenarios that molecular targeted therapies may succeed. Among known oncogenes, the epidermal growth factor receptor (EGFR) has b...

Full description

Bibliographic Details
Main Authors:	Rolando ePerez, Tania eCrombet, Joel ede Leon, Ernesto eMoreno
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-04-01
Series:	Frontiers in Pharmacology
Subjects:	EGFR targeted therapy cetuximab combination therapy erlotinib oncogene addiction
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00053/full

Similar Items

Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways
by: Dmitri Kamashev, et al.
Published: (2023-08-01)

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects
by: Tania Crombet, et al.
Published: (2011-04-01)

Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients
by: Gerber Peter, et al.
Published: (2012-02-01)

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
by: Amanda C. Sharko, et al.
Published: (2021-01-01)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
by: Cavazzoni Andrea, et al.
Published: (2012-12-01)

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
by: Miriam Grazia Ferrara, et al.
Published: (2020-05-01)

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer
by: Li MA, et al.
Published: (2009-12-01)

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review
by: David John McMahon, et al.
Published: (2024-01-01)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.
by: Alessandro eOttaiano, et al.
Published: (2013-01-01)

Targeting EGFR and Monitoring Tumorigenesis of Human Lung Cancer Cells In Vitro and In Vivo Using Nanodiamond-Conjugated Specific EGFR Antibody
by: Yu-Wei Lin, et al.
Published: (2022-12-01)

Epidermal growth factor receptor (EGFR) mutation status and Rad51 determine the response of glioblastoma (GBM) to multimodality therapy with cetuximab, temozolomide and radiation
by: Phyllis Rachelle Wachsberger, et al.
Published: (2013-02-01)

Targeting Non-Oncogene Addiction for Cancer Therapy
by: Hae Ryung Chang, et al.
Published: (2021-01-01)

Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer
by: Rui Ni, et al.
Published: (2023-03-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
by: Vivek Subbiah, et al.
Published: (2020-04-01)

Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC
by: Pierre Coliat, et al.
Published: (2019-10-01)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
by: Meiqin Yuan, et al.
Published: (2022-03-01)

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
by: Antonio Rossi, et al.
Published: (2022-02-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II
by: Keqiang Zhang, et al.
Published: (2020-09-01)

Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
by: Jacqueline V. Aredo, et al.
Published: (2022-01-01)

Photosensitive EGFR-Targeted Nanocarriers for Combined Photodynamic and Local Chemotherapy
by: Elena de las Heras, et al.
Published: (2022-02-01)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
by: Adithya Chennamadhavuni, et al.
Published: (2022-06-01)

BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis
by: Fangyuan Li, et al.
Published: (2023-12-01)

The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting—A Nation-Wide Retrospective Analysis (RACER)
by: Paweł Michał Potocki, et al.
Published: (2023-09-01)

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs
by: Jun CHEN, et al.
Published: (2010-04-01)

VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancerResearch in context
by: Junxian Yu, et al.
Published: (2023-03-01)

EGFR-Based Targeted Therapy for Colorectal Cancer—Promises and Challenges
by: Balakarthikeyan Janani, et al.
Published: (2022-03-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors
by: Natalie Carroll, et al.
Published: (2022-11-01)

Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future
by: Chancellor E. Donald, et al.
Published: (2011-12-01)

Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene-expressing transgenic zebrafish model
by: Yan Li, et al.
Published: (2019-10-01)

Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies
by: Khalid Alhazzani, et al.
Published: (2023-10-01)

Targeting Non-Oncogene Addiction: Focus on Thyroid Cancer
by: Maria Chiara Anania, et al.
Published: (2020-01-01)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020-03-01)

Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines
by: Gennaro Altamura, et al.
Published: (2022-11-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
by: Lu Yang, et al.
Published: (2022-06-01)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015-09-01)

Review of EGFR TKIs in metastatic NSCLC, including ongoing trials
by: Barbara eMelosky
Published: (2014-09-01)

Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth
by: Dmitry Kamashev, et al.
Published: (2021-03-01)